Quantitative analysis of drug delivery to the brain via nasal route. 2014

Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
Department of Clinical Biochemistry and Pharmacology, The Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.

The blood-brain barrier (BBB) prevents drugs' permeability into the brain and limits the management of brain diseases. Intranasal delivery is a convenient route of drug administration that can bypass the BBB and lead to a direct delivery of the drug to the brain. Indeed, drug accumulation in the brain following intranasal application of a drug solution, or of a drug encapsulated in specialized delivery systems (DDSs), has been reported in numerous scientific publications. We aimed to analyze the available quantitative data on drug delivery to the brain via the nasal route and to reveal the efficiency of brain drug delivery and targeting by different types of nasally-administered DDSs. We searched for scientific publications published in 1970-2014 that reported delivery of drugs or model compounds to the brain via intranasal and parenteral routes, and contained quantitative data that were sufficient for calculation of brain targeting efficiency. We identified 73 publications (that reported data on 82 compounds) that matched the search criteria and analyzed their experimental settings, formulation types, analytical methods, and the claimed efficiencies of drug brain targeting: drug targeting efficiency (%DTE) and nose-to-brain direct transport (%DTP). Outcomes of this analysis indicate that efficiency of brain delivery by the nasal route differs widely between the studies, and does not correlate with the drug's physicochemical properties. Particle- and gel-based DDSs offer limited advantage for brain drug delivery in comparison to the intranasal administration of drug solution. Nevertheless, incorporation of specialized reagents (e.g., absorption enhancers, mucoadhesive compounds, targeting residues) can increase the efficiency of drug delivery to the brain via the nasal route. More elaborate and detailed methodological and analytical characterizations and standardized reporting of the experimental outcomes are required for reliable quantification of drug targeting to the brain by the nasal route. Quantitative analysis of these data will facilitate the development of DDSs with high brain targeting efficiency.

UI MeSH Term Description Entries
D001921 Brain The part of CENTRAL NERVOUS SYSTEM that is contained within the skull (CRANIUM). Arising from the NEURAL TUBE, the embryonic brain is comprised of three major parts including PROSENCEPHALON (the forebrain); MESENCEPHALON (the midbrain); and RHOMBENCEPHALON (the hindbrain). The developed brain consists of CEREBRUM; CEREBELLUM; and other structures in the BRAIN STEM. Encephalon
D004364 Pharmaceutical Preparations Drugs intended for human or veterinary use, presented in their finished dosage form. Included here are materials used in the preparation and/or formulation of the finished dosage form. Drug,Drugs,Pharmaceutical,Pharmaceutical Preparation,Pharmaceutical Product,Pharmaceutic Preparations,Pharmaceutical Products,Pharmaceuticals,Preparations, Pharmaceutical,Preparation, Pharmaceutical,Preparations, Pharmaceutic,Product, Pharmaceutical,Products, Pharmaceutical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000281 Administration, Intranasal Delivery of medications through the nasal mucosa. Drug Administration, Intranasal,Administration, Intranasal Drug,Administration, Nasal,Intranasal Administration,Intranasal Drug Administration,Administrations, Intranasal,Administrations, Intranasal Drug,Administrations, Nasal,Drug Administrations, Intranasal,Intranasal Administrations,Intranasal Drug Administrations,Nasal Administration,Nasal Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D016503 Drug Delivery Systems Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity. Drug Targeting,Delivery System, Drug,Delivery Systems, Drug,Drug Delivery System,Drug Targetings,System, Drug Delivery,Systems, Drug Delivery,Targeting, Drug,Targetings, Drug

Related Publications

Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
August 2001, Yao xue xue bao = Acta pharmaceutica Sinica,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
June 2025, Expert opinion on drug delivery,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
January 2023, Journal of pharmaceutical investigation,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
December 2017, Journal of controlled release : official journal of the Controlled Release Society,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
June 2020, Nanomaterials (Basel, Switzerland),
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
June 2004, Pharmacy world & science : PWS,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
January 2019, Current drug delivery,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
June 2025, MedComm,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
July 2024, Drug delivery and translational research,
Luba Kozlovskaya, and Mohammed Abou-Kaoud, and David Stepensky
February 2022, Pharmaceuticals (Basel, Switzerland),
Copied contents to your clipboard!